2024
Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease
HAVRANKOVA, Petra; Jan ROTH; Vaclav CAPEK; Jiri KLEMPIR; Marek BALÁŽ et. al.Základní údaje
Originální název
Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease
Autoři
HAVRANKOVA, Petra (203 Česká republika); Jan ROTH (203 Česká republika); Vaclav CAPEK (203 Česká republika); Jiri KLEMPIR (203 Česká republika); Marek BALÁŽ (703 Slovensko, domácí); Irena REKTOROVÁ (203 Česká republika, domácí); Vladimir HAN (203 Česká republika); Matej SKORVANEK (203 Česká republika); Karin GMITTEROVA (203 Česká republika); Michal MINAR (203 Česká republika); Peter VALKOVIC (203 Česká republika); Michaela KAISEROVA (203 Česká republika); Petr KANOVSKY (203 Česká republika); Milan GROFIK (203 Česká republika); Egon KURCA (203 Česká republika); Jan NECPAL (203 Česká republika) a Robert JECH (203 Česká republika)
Vydání
Neurologia i neurochirurgia polska, GDANSK, VIA MEDICA, 2024, 0028-3843
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Polsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.600
Kód RIV
RIV/00216224:14110/24:00138483
Organizační jednotka
Lékařská fakulta
UT WoS
001360325600001
EID Scopus
2-s2.0-85213726825
Klíčová slova česky
acute polyneuropathy; Parkinson's Disease; levodopa/carbidopa intestinal gel; levodopa equivalent daily dose
Klíčová slova anglicky
acute polyneuropathy; Parkinson's Disease; levodopa/carbidopa intestinal gel; levodopa equivalent daily dose
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 2. 2025 13:24, Mgr. Tereza Miškechová
Anotace
V originále
Aim of study. To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study. Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation.The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods. A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results. Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation.The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695-3,184) and 1,898 (1,484-2,167) mg, respectively.The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications. The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.
Návaznosti
| LX22NPO5107, projekt VaV |
| ||
| 90249, velká výzkumná infrastruktura |
|